Accent Therapeutics, Inc. announced that it will issue 91,155,166 series C preferred shares of par value of $0.00001 per share at an issue price of $0.83 per share for gross proceeds of $75,658,788 in funding on December 20, 2023. The shares are convertible into common shares at a fixed conversion price of $0.83 per share. The shares carry non-cumulative dividend at the rate of $0.0664 per share per annum.

The shares are non-redeemable. The round is raised at a post money valuation of $156,687,152.